CompletedPHASE1, PHASE2NCT05074472
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
Studying Carcinoma of gallbladder and extrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ZielBio, Inc.
- Principal Investigator
- Ramesh Ramanathan, MDZielBio, Inc.
- Intervention
- ZB131(drug)
- Enrollment
- 35 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2023
Study locations (9)
- Mayo Clinic - Phoenix, Phoenix, Arizona, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Mayo Clinic - Rochester, Rochester, Minnesota, United States
- Sarah Cannon Research Institute, Nashville, Tennessee, United States
- NEXT Oncology, Austin, Texas, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- NEXT Oncology, San Antonio, Texas, United States
- University of Virginia, Charlottesville, Virginia, United States
- NEXT Onoology, Fairfax, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05074472 on ClinicalTrials.govOther trials for Carcinoma of gallbladder and extrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT06901622Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic CholangiocarcinomaThe First Affiliated Hospital of Zhengzhou University
- RECRUITINGNCT07337850Prospective Evaluation of 68Ga-FAPI PET in Biliary CancersTata Memorial Centre
- RECRUITINGPHASE2NCT06440993Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- ACTIVE NOT RECRUITINGPHASE2NCT05712356A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsLisata Therapeutics, Inc.
- ENROLLING BY INVITATIONPHASE3NCT06671418Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary ObstructionErasmus Medical Center
- RECRUITINGNCT05404347NGS in Gallbladder Cancer and Response to TreatmentBanaras Hindu University
See all trials for Carcinoma of gallbladder and extrahepatic biliary tract →